valdecoxib
Term · Oncology and biomedicine · MLC-T-ONC-009149
A substance that is being studied as a treatment for pain and other side effects of cancer therapy. It belongs to the family of drugs called COX-2 inhibitors.
A sulfonamide derivative and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. Valdecoxib selectively binds to and inhibits cyclooxygenase (COX)-2, thereby preventing the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever. This NSAID does not inhibit COX-1 at therapeutic concentrations and therefore does not interfere with blood coagulation.
| Identifier | MLC-T-ONC-009149 |
|---|---|
| Field | Oncology and biomedicine |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009149",
"term": "valdecoxib",
"field": "Oncology and biomedicine",
"definitions": [
"A substance that is being studied as a treatment for pain and other side effects of cancer therapy. It belongs to the family of drugs called COX-2 inhibitors.",
"A sulfonamide derivative and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic activities. Valdecoxib selectively binds to and inhibits cyclooxygenase (COX)-2, thereby preventing the conversion of arachidonic acid into prostaglandins, which are involved in the regulation of pain, inflammation, and fever. This NSAID does not inhibit COX-1 at therapeutic concentrations and therefore does not interfere with blood coagulation."
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/valdecoxib/"
}
Record 17,087 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.